Skip to main content
FRMSL logo

FRMSL — Investor Relations & Filings

Ticker · 4746 ISIN · TW0004746003 TW Manufacturing
Open in API
Filings indexed 1,872 across all filing types
Latest filing 2021-06-09 Director's Dealing
Country TW Taiwan
Listing TW 4746

About FRMSL

www.formosalab.com

Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company provides integrated services ranging from process development and custom synthesis to large-scale commercial manufacturing. Its core product portfolio includes UV-filters, Vitamin D derivatives, and polymers such as cholesterol and phosphate binders. Formosa Laboratories offers specialized expertise in Antibody-Drug Conjugates (ADCs) and injectable manufacturing, including cytotoxic and freeze-dried products. Maintaining high quality standards, its facilities are cGMP-compliant and have been successfully inspected by the US FDA, TFDA, EDQM, and PMDA. The company serves a global clientele, providing one-stop solutions for complex chemical synthesis, fermentation, and peptide production.

Recent filings

Filing Released Lang Actions
110年05月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and related parties of the company 台耀化學股份有限公司. It lists shareholdings by directors, supervisors, and senior management, including pledged shares and related ratios. The document does not contain financial statements, earnings data, or management discussion. It is a disclosure of insider shareholdings and pledges, which corresponds to a Director's Dealing report or insider share transactions. There is no indication of a general meeting, voting results, or other report types. The document length is about 4681 characters, which is sufficient for a detailed insider shareholding report. Therefore, the best fitting category is Director's Dealing (DIRS).
2021-06-09 Chinese
110年5月背書保證與資金貸與
Capital/Financing Update Classification · 90% confidence The document is a financial disclosure from a listed company (台耀) providing details about fund lending balances and endorsement guarantees for the current and previous months, including limits and cumulative amounts. The content is concise, numerical, and relates to capital or financing activities, specifically about fund lending and guarantees. It does not contain comprehensive financial statements or management discussion, nor is it an announcement of a report publication. Given the focus on financing-related data and the nature of the information, the document best fits the category of Capital/Financing Update (CAP). The document length is short but contains substantive financial data related to capital activities, not just an announcement or certification.
2021-06-04 Chinese
110年5月營業收入
Interim / Quarterly Report Classification · 95% confidence The document is a summarized revenue report from a listed company (台耀) showing monthly and cumulative net operating revenue figures with comparisons to the previous year. It includes notes on accounting standards (IFRS) and reporting requirements. The document length is short (772 characters) and it primarily provides financial data for a specific month and year (May 2021). This matches the characteristics of an Interim / Quarterly Report (IR), which contains substantive financial data for a period shorter than a full fiscal year. It is not an announcement or a brief summary but actual financial figures and explanations, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the best classification is IR (Interim / Quarterly Report). Q1 2021
2021-06-04 Chinese
代重要子公司台新藥公告台新藥與遠大醫簽訂授權協議
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (台耀) disclosing a licensing agreement between its subsidiary and another pharmaceutical company. It includes details about the contract, approval by the board, and potential financial impact. The document is short (1097 characters) and structured as a formal disclosure rather than a full report. It does not contain financial statements, detailed financial analysis, or comprehensive management discussion. It is an announcement of a material contract/licensing agreement, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or M&A Activity. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-06-03 Chinese
代重要子公司公告台新藥董事會決議藥物對外授權案
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (4746 台耀) reporting a board resolution of its important subsidiary regarding an external licensing agreement for a drug. It includes details about the decision, the drug involved, and the business implications. The document is short (824 characters) and serves as a factual disclosure rather than a full report or detailed financial statement. It does not contain financial results, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive information about a corporate event. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-06-02 Chinese
本公司可轉換公司債台耀三(代號47463)近期達公布注意交易 資訊標準，故公告相關訊息，以利投資人區別瞭解。
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a listed company (台耀) regarding convertible bonds (台耀三) reaching a trading attention threshold. It provides details about the convertible bonds, such as maturity date, issuance amount, conversion price, and market prices. The document references regulatory compliance and disclosure procedures but does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a capital market instrument rather than a full financial report or earnings release. The document length is short (1089 characters), and it is primarily an informational disclosure to investors about convertible bond trading status. Therefore, it fits best under Capital/Financing Update (CAP).
2021-05-24 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.